Search peptides, terms, sources/
5 peptides

Immune and longevity

Immune and longevity peptides are studied for effects on immune cells, inflammation, cell energy and biological ageing. The group holds thymosin alpha-1, epithalon and KPV, plus two peptides that act on mitochondria, the parts of a cell that make its energy: elamipretide and MOTS-c. None is licensed in the UK. The evidence ranges from lab and animal work to one failed phase 3 trial, so read each peptide's grade on its own.

Which peptides are in this family?

  • Elamipretide

    Synthetic four-amino-acid peptide studied in rare mitochondrial diseases. US accelerated approval for Barth syndrome; not authorised in the UK. A large phase 3 trial failed.

    Immune and longevityHuman trialsEvidence reviewed
    PreliminaryNot licensed in the UK
  • EpithalonEpitalon

    Synthetic four-amino-acid peptide studied in ageing research. Not licensed in the UK; evidence is mostly laboratory and animal work from one group.

    Immune and longevityHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • KPVLys-Pro-Val

    Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

    Immune and longevityAnimal studiesEvidence reviewed
    PreliminaryNot licensed in the UK
  • MOTS-cMitochondrial open reading…

    16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells. Not licensed in the UK. No published trial gave MOTS-c to people; human studies measured the body's own levels.

    Immune and longevityHuman trialsEvidence reviewed
    PreliminaryNot licensed in the UK
  • Thymosin Alpha-1Thymalfasin

    Immune-regulating peptide studied in sepsis, pancreatitis and hepatitis B. Not licensed in the UK; meta-analyses show mixed results.

    Immune and longevityHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

Best recorded finding for each peptide in this family

Each row grades one recorded finding, not the peptide or the medicine.

PeptideUK statusFindingEvidence grade
ElamipretideNot licensed in the UKBarth syndrome, 168-week extensionPreliminary
EpithalonNot licensed in the UKEx-vivo elderly donor lymphocytesLimited
KPVNot licensed in the UKPepT1 uptake, cells and micePreliminary
MOTS-cNot licensed in the UKDiscovery paper, mice and cellsPreliminary
Thymosin Alpha-1Not licensed in the UKSepsis 28-day mortalityModerate

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.